September 4, 2025
We are pleased to have served as Commercial Due Diligence (CDD) advisors to Partners Group, a global private markets leader, in its strategic investment in U.S.-based restor3d. Partners Group will acquire a significant minority stake, bringing total funding to $104 million; $65 million from Partners Group and $39 million from existing shareholders.
Founded in 2017, restor3d is transforming orthopedic care through personalized solutions. Its proprietary AI-powered design software, vertically integrated additive manufacturing, and rapid surgical planning enable implants tailored to both surgeon preferences and patient anatomy.
“Working alongside Partners Group on this strategic investment demonstrates our role as a trusted advisor in advancing innovative healthcare solutions,” said Michal Raciborski, Managing Partner, Financial Sponsors at Alira Health. “We are proud to have supported Partners Group in a transaction that will help accelerate the growth of personalized orthopedic care.”
“Personalized orthopedic solutions represent a critical step forward in improving surgical outcomes and patient care,” said Matteo Tolomei, Co-Chair of Alira Health’s Orthopedics and Robotic-Assisted Surgery (RAS) Center of Excellence. “Innovations like restor3d’s platform demonstrate the power of technology to deliver implants that truly adapt to the needs of each patient.”
This engagement underscores Alira Health’s role as a trusted advisor to investors shaping the future of life sciences. Our work supports confident, growth-oriented decisions that help advance innovation across the healthcare sector. For more details, read the full press release. To learn more about Alira Health’s Commercial Due Diligence services, visit AliraHealth.com.
Subscribe to our newsletter for the latest news, events, and thought leadership